| DC47591 |
JAK-IN-14
|
JAK-IN-14 is a potent and selective JAK1 inhibitor, with an IC50 of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16). |
| DC47590 |
Ten01
|
Ten01 has 5.0 nM activity against JAK1 kinase. |
| DC47132 |
JAK1-IN-8
|
JAK1-IN-8, a potent JAK1 inhibitor (IC50<500 nM), compound 28, extracted from patent WO2016119700A1. |
| DC47066 |
Ifidancitinib
|
Ifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Ifidancitinib can be used in studies of allergies, asthma and autoimmune diseases. |
| DC47041 |
Lorpucitinib
|
Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease. |
| DC47039 |
Itacnosertib
|
Itacnosertib (TP-0184) is both inhibitor to JAK2, ACVR1 (ALK2) and ALK5 as described in WO2014151871. |
| DC47030 |
Ilunocitinib
|
Ilunocitinib (compound 27) is a JAK inhibitor (extracted from patent WO2009114512A1). |
| DC46857 |
Nezulcitinib
|
Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (JAK) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation. |
| DC46856 |
JAK2/FLT3-IN-1 TFA
|
JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity. |
| DC46855 |
Deuruxolitinib
|
Deuruxolitinib (CTP-543), a deuterated Ruxolitinib, modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I). |
